METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS

WIPO Patent Application WO2005000244

A3

This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha 4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin ( 4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.

WO/2005/078081	USE OF COMPOUNDS THAT REGULATE HDAC6 TUBULIN DEACETYLASE ACTIVITY IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, METHOD OF IDENTIFYING THE AFOREMENTIONED REGULATING COMPOUNDS, SAID PHARMACEUTICAL COMPOUNDS AND APPLICATIONS THEREOF
JPS54106448	N ALPHAAALKYLSULFONYL OMEGAAAMIDINOPHENYLL ALPHAAAMINOALKYL CARBOXYLIC ACID AMIDE AND N ALPHAAAMIDINOPHENYLLALPHAAAMINOALKYL CARBOXILIC AMIDE
JP5335191	Compositions and Methods for Treating Diseases Related to Trp-p8 Expression

YEDNOCK THEODORE A (US)
FREEDMAN STEPHEN B (US)
LIEBERBURG IVAN (US)
PLEISS MICHAEL A (US)
KONRADI ANDREI W (US)
SHOPP GEORGE (US)
MESSERSMITH ELIZABETH (US)

PCT/US2004/020240

September 29, 2005

June 25, 2004

Click for automatic bibliography generation  

ELAN PHARM INC (US)
YEDNOCK THEODORE A (US)
FREEDMAN STEPHEN B (US)
LIEBERBURG IVAN (US)
PLEISS MICHAEL A (US)
KONRADI ANDREI W (US)
SHOPP GEORGE (US)
MESSERSMITH ELIZABETH (US)

A61K31/16; A61K31/18; A61K31/195; A61K31/40; A61K31/415; A61K31/425; A61K31/44; A61K31/519; A61K31/525; A61K38/00; A61K39/00; A61K39/395; A61K; (IPC1-7): A61K39/395; A61K38/00; A61K39/00

WO1997018838A1

1997-05-29

US6270766B1	2001-08-07
US20020198172A1	2002-12-26

BARBADILLO ET AL: "Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthrtis", SPRINGER SEMIN IMMUNOTHERAPY, vol. 16, no. 4, 1995, pages 427 - 436, XP001199800
BARBADILLO ET AL: "Anti-VLA-4 mAB prevents adjuvant arthritis in Lewis rats", ARTHR RHEUM, vol. 36, no. 95, 1993, pages S95, XP008051023
ISSEKUTZ A. C. ET AL: "Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late activation antigen 4 integrin mechanisms", J EXP MED, vol. 181, no. 3, 1 March 1995 (1995-03-01), pages 1197 - 1203, XP002986932
SEIFFGE D. ET AL: "Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats", J RHEUMATOL, vol. 23, no. 12, 1996, pages 2086 - 2091, XP001199773
ZEIDLER ET AL: "Therapeutic effects of antibodies against adhesion molecules in murine collagen type II-induced arthritis", AUTOIMMUNITY, vol. 21, no. 4, 1995, pages 245 - 252, XP001199794
"FDA Alert for Healthcare Professionals Natalizumab (marketed as Tysabri)", WEITZ AND LUXENBERG, 8 April 2005 (2005-04-08), XP002987569, Retrieved from the Internet

View/Download PDF      PDF Help

Previous Patent: THE POLYMORPHIC FORM A OF 4-[6-ACETYL-3-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO)PROPOXY]-2-PROPYLP...

Next Patent: COMPOSITIONS AND METHODS FOR INCREASING TELOMERASE ACTIVITY